SecBot SecBot
8-K ·Filed Aug 10, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 5/10
Horizonweeks Processed3mo ago SEC0001743881-26-000026
8-K Item 2.02: Earnings release
Actionable Insight • Neutral

Attruby revenue trajectory ($222.4M in Q2 vs $180.6M in Q1) shows accelerating adoption, and three PDUFA dates in the next 9 months create a dense catalyst calendar. The $0.78 EPS miss vs $0.64 consensus is notable but typical for a commercial-stage biotech investing heavily in launches; the key driver is the BBP-418 PDUFA in November 2026.

DirectionNeutral
Confidencehigh
Horizonweeks

Price Chart

Loading chart...

Executive Summary

BridgeBio reported Q2 2026 revenue of $243.7M, more than doubling YoY, driven by $222.4M in Attruby sales. The company continues to narrow its net loss to $152.2M ($0.78/share), but still meaningfully missed consensus EPS estimates ($0.78 actual vs $0.64 consensus). Key milestones include Priority Review for BBP-418 (PDUFA Nov 27, 2026), encaleret (PDUFA May 8, 2027), and a $1B preferred equity financing completed post-quarter. The strong top-line growth and regulatory progress are offset by persistent operating losses and a net-loss-per-share that missed expectations.

Key Financial Metrics

EPS
−$0.78
est −$0.64 · -21.9%
Revenue
$243.7M
Rating
miss
Free Cash Flow
-$292.3M

Key Facts

  • Total Q2 2026 revenues were $243.7M, up from $110.6M YoY, with Attruby product revenue of $222.4M
  • Net loss per share for Q2 2026 was $0.78, compared to consensus of $0.64
  • Cash, cash equivalents and marketable securities totaled $720.2M at June 30, 2026, with an additional $1B closed on July 1, 2026 in preferred equity
  • BBP-418 NDA accepted with Priority Review, PDUFA target action date November 27, 2026
  • Encaleret for ADH1 received Priority Review, PDUFA target action date May 8, 2027
  • NDA submitted for oral infigratinib in achondroplasia, with U.S. launch expected mid-2027
  • Real-world evidence published showing acoramidis associated with 37% reduction in composite CV events vs tafamidis at 6 months

Financial Impact

$243.7M in quarterly revenue; revenues doubled YoY, but net loss per share of $0.78 missed Street consensus of $0.64

revenueepsnet loss

Risk Factors

  • EPS continuing to miss consensus as operating costs scale ahead of revenue growth
  • Attruby market share growth may slow as tafamidis (Vyndamax) maintains entrenched position
  • Pipeline program failures or FDA rejections at upcoming PDUFA dates
  • High debt load ($2.48B in notes + deferred royalty obligations) with ongoing negative operating cash flow

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (28 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001743881-26-000026
Document: bbio-20260810.htm0001743881-26-000026
Document: 0001743881-26-000026-index-headers.html0001743881-26-000026
Document: 0001743881-26-000026-index.html0001743881-26-000026
Document: 0001743881-26-000026.txt0001743881-26-000026
8-K Data (Synthetic)0001743881-26-000026

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 58m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 10, 2026